Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > The issue of the safe use of higher doses of vaccinia virus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5610)
•••
Comment by Noteableon Jul 21, 2023 11:57am
319 Views
Post# 35551614

RE:RE:RE:RE:RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus

RE:RE:RE:RE:RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus Vaccina Virus (smallpox virus) is a DNA virus and not an RNA virus like ONCY's pelareorep.

Two Republican lawmakers in Idaho intended to criminalize the use of all RNA viruses across the state.

"Misinformed individuals have gained political power and are currently trying to use their positions to advance agendas that will limit citizens choices," said Dr. Daniel Griffin, chief of infectious diseases at Optum Care, a network of health care providers.

Bill HB 154 was referred to the House Health and Welfare Committee and did not proceed forward.

https://www.usatoday.com/story/news/nation/2023/02/21/idaho-mrna-covid-19-vaccines/11316055002/

https://www.idmed.org/idaho/Idaho_Public/IMA_Legislative_Program/IMA_Bill_Tracker/Idaho_Public/Advocacy/2023_IMA_Bill_Tracker.aspx?hkey=efa89174-ef45-4a6e-9085-ad49b58df222
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities